Akero Capital Surpluse vs Net Invested Capital Analysis

AKRO Stock

USD 19.48 1.02 4.98%

Akero Therapeutics financial indicator trend analysis is way more than just evaluating Akero Therapeutics prevailing accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Akero Therapeutics is a good investment. Please check the relationship between Akero Therapeutics Capital Surpluse and its Net Invested Capital accounts. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Akero Therapeutics. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in metropolitan statistical area.

To learn how to invest in Akero Stock, please use our How to Invest in Akero Therapeutics guide.

Capital Surpluse vs Net Invested Capital

Capital Surpluse vs Net Invested Capital Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Akero Therapeutics Capital Surpluse account and Net Invested Capital. At this time, the significance of the direction appears to have very strong relationship.

The correlation between Akero Therapeutics' Capital Surpluse and Net Invested Capital is 0.88. Overlapping area represents the amount of variation of Capital Surpluse that can explain the historical movement of Net Invested Capital in the same time period over historical financial statements of Akero Therapeutics, assuming nothing else is changed. The correlation between historical values of Akero Therapeutics' Capital Surpluse and Net Invested Capital is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Capital Surpluse of Akero Therapeutics are associated (or correlated) with its Net Invested Capital. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Net Invested Capital has no effect on the direction of Capital Surpluse i.e., Akero Therapeutics' Capital Surpluse and Net Invested Capital go up and down completely randomly.

Correlation Coefficient

0.88

Relationship Direction	Positive
Relationship Strength	Strong

View All Relationships

Capital Surpluse

Net Invested Capital

The total amount of capital invested in a company, including both equity and debt, minus any cash or cash equivalents.

Most indicators from Akero Therapeutics' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Akero Therapeutics current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Akero Therapeutics. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in metropolitan statistical area.

To learn how to invest in Akero Stock, please use our How to Invest in Akero Therapeutics guide.As of the 23rd of May 2024, Selling General Administrative is likely to drop to about 29 K. In addition to that, Issuance Of Capital Stock is likely to drop to about 180.6 M

Akero Therapeutics fundamental ratios Correlations

	Total Assets	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Net Tangible Assets	Net Debt	Retained Earnings	Accounts Payable	Cash	Non Current Assets Total	Non Currrent Assets Other	Other Assets	Cash And Short Term Investments	Common Stock Shares Outstanding	Non Current Liabilities Total	Other Current Assets	Total Liab	Net Invested Capital	Total Current Assets	Net Working Capital	Capital Surpluse	Non Current Liabilities Other	Short Long Term Debt Total	Property Plant And Equipment Net	Net Receivables	Capital Lease Obligations
Total Assets		0.74	0.79	0.99	0.96	-0.91	-0.98	0.82	0.87	0.89	0.11	0.12	1.0	0.75	0.08	0.97	0.28	0.99	1.0	1.0	0.88	0.33	0.91	-0.93	0.79	-0.91
Other Current Liab	0.74		0.99	0.74	0.81	-0.87	-0.82	0.89	0.87	0.48	0.7	0.72	0.75	0.58	-0.11	0.76	0.17	0.73	0.75	0.73	0.86	0.71	0.46	-0.66	0.81	-0.71
Total Current Liabilities	0.79	0.99		0.78	0.85	-0.9	-0.87	0.95	0.91	0.51	0.66	0.67	0.79	0.67	-0.06	0.79	0.22	0.78	0.79	0.78	0.92	0.72	0.53	-0.73	0.87	-0.77
Total Stockholder Equity	0.99	0.74	0.78		0.98	-0.89	-0.97	0.81	0.85	0.88	0.12	0.13	0.99	0.76	-0.06	0.95	0.14	1.0	0.99	0.99	0.89	0.34	0.9	-0.92	0.79	-0.91
Net Tangible Assets	0.96	0.81	0.85	0.98		-0.94	-0.96	0.86	0.91	0.77	0.23	0.26	0.97	0.74	-0.12	0.9	0.1	0.98	0.97	0.96	0.93	0.5	0.81	-0.88	0.79	-0.87
Net Debt	-0.91	-0.87	-0.9	-0.89	-0.94		0.92	-0.89	-0.98	-0.62	-0.35	-0.38	-0.92	-0.6	-0.1	-0.83	-0.33	-0.88	-0.91	-0.91	-0.92	-0.61	-0.67	0.78	-0.76	0.79
Retained Earnings	-0.98	-0.82	-0.87	-0.97	-0.96	0.92		-0.91	-0.9	-0.83	-0.24	-0.24	-0.98	-0.79	-0.08	-0.96	-0.3	-0.97	-0.98	-0.98	-0.92	-0.42	-0.87	0.95	-0.89	0.95
Accounts Payable	0.82	0.89	0.95	0.81	0.86	-0.89	-0.91		0.92	0.55	0.53	0.52	0.83	0.8	0.05	0.8	0.3	0.8	0.83	0.81	0.95	0.7	0.62	-0.83	0.94	-0.84
Cash	0.87	0.87	0.91	0.85	0.91	-0.98	-0.9	0.92		0.56	0.37	0.41	0.88	0.64	0.1	0.79	0.34	0.84	0.88	0.87	0.95	0.64	0.62	-0.76	0.78	-0.75
Non Current Assets Total	0.89	0.48	0.51	0.88	0.77	-0.62	-0.83	0.55	0.56		-0.14	-0.15	0.88	0.71	0.08	0.93	0.2	0.89	0.88	0.89	0.63	-0.07	0.97	-0.88	0.66	-0.84
Non Currrent Assets Other	0.11	0.7	0.66	0.12	0.23	-0.35	-0.24	0.53	0.37	-0.14		0.99	0.12	0.21	-0.17	0.2	0.02	0.11	0.12	0.1	0.36	0.81	-0.2	-0.06	0.41	-0.19
Other Assets	0.12	0.72	0.67	0.13	0.26	-0.38	-0.24	0.52	0.41	-0.15	0.99		0.13	0.16	-0.19	0.19	0.0	0.12	0.13	0.11	0.37	0.83	-0.22	-0.04	0.37	-0.16
Cash And Short Term Investments	1.0	0.75	0.79	0.99	0.97	-0.92	-0.98	0.83	0.88	0.88	0.12	0.13		0.75	0.08	0.96	0.28	0.99	1.0	1.0	0.89	0.34	0.9	-0.93	0.79	-0.91
Common Stock Shares Outstanding	0.75	0.58	0.67	0.76	0.74	-0.6	-0.79	0.8	0.64	0.71	0.21	0.16	0.75		-0.08	0.76	0.1	0.77	0.75	0.75	0.82	0.37	0.74	-0.85	0.87	-0.78
Non Current Liabilities Total	0.08	-0.11	-0.06	-0.06	-0.12	-0.1	-0.08	0.05	0.1	0.08	-0.17	-0.19	0.08	-0.08		0.08	0.96	-0.06	0.08	0.09	-0.06	-0.17	0.09	-0.05	0.0	-0.02
Other Current Assets	0.97	0.76	0.79	0.95	0.9	-0.83	-0.96	0.8	0.79	0.93	0.2	0.19	0.96	0.76	0.08		0.28	0.95	0.96	0.96	0.82	0.26	0.91	-0.93	0.83	-0.93
Total Liab	0.28	0.17	0.22	0.14	0.1	-0.33	-0.3	0.3	0.34	0.2	0.02	0.0	0.28	0.1	0.96	0.28		0.14	0.28	0.28	0.19	0.04	0.21	-0.24	0.23	-0.22
Net Invested Capital	0.99	0.73	0.78	1.0	0.98	-0.88	-0.97	0.8	0.84	0.89	0.11	0.12	0.99	0.77	-0.06	0.95	0.14		0.99	0.99	0.88	0.32	0.91	-0.93	0.79	-0.91
Total Current Assets	1.0	0.75	0.79	0.99	0.97	-0.91	-0.98	0.83	0.88	0.88	0.12	0.13	1.0	0.75	0.08	0.96	0.28	0.99		1.0	0.88	0.34	0.9	-0.93	0.79	-0.91
Net Working Capital	1.0	0.73	0.78	0.99	0.96	-0.91	-0.98	0.81	0.87	0.89	0.1	0.11	1.0	0.75	0.09	0.96	0.28	0.99	1.0		0.88	0.32	0.91	-0.93	0.78	-0.91
Capital Surpluse	0.88	0.86	0.92	0.89	0.93	-0.92	-0.92	0.95	0.95	0.63	0.36	0.37	0.89	0.82	-0.06	0.82	0.19	0.88	0.88	0.88		0.6	0.69	-0.85	0.89	-0.81
Non Current Liabilities Other	0.33	0.71	0.72	0.34	0.5	-0.61	-0.42	0.7	0.64	-0.07	0.81	0.83	0.34	0.37	-0.17	0.26	0.04	0.32	0.34	0.32	0.6		-0.03	-0.22	0.47	-0.31
Short Long Term Debt Total	0.91	0.46	0.53	0.9	0.81	-0.67	-0.87	0.62	0.62	0.97	-0.2	-0.22	0.9	0.74	0.09	0.91	0.21	0.91	0.9	0.91	0.69	-0.03		-0.94	0.71	-0.9
Property Plant And Equipment Net	-0.93	-0.66	-0.73	-0.92	-0.88	0.78	0.95	-0.83	-0.76	-0.88	-0.06	-0.04	-0.93	-0.85	-0.05	-0.93	-0.24	-0.93	-0.93	-0.93	-0.85	-0.22	-0.94		-0.9	0.97
Net Receivables	0.79	0.81	0.87	0.79	0.79	-0.76	-0.89	0.94	0.78	0.66	0.41	0.37	0.79	0.87	0.0	0.83	0.23	0.79	0.79	0.78	0.89	0.47	0.71	-0.9		-0.89
Capital Lease Obligations	-0.91	-0.71	-0.77	-0.91	-0.87	0.79	0.95	-0.84	-0.75	-0.84	-0.19	-0.16	-0.91	-0.78	-0.02	-0.93	-0.22	-0.91	-0.91	-0.91	-0.81	-0.31	-0.9	0.97	-0.89

Click cells to compare fundamentals

Akero Therapeutics Account Relationship Matchups

Akero Therapeutics fundamental ratios Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Total Assets	138.1M	273.3M	195.5M	356.6M	580.3M	609.3M
Other Current Liab	8.4M	9.4M	18.2M	10.8M	11.8M	9.4M
Total Current Liabilities	9.4M	13.1M	25.1M	19.1M	19.1M	13.9M
Total Stockholder Equity	128.7M	258.7M	169.1M	326.6M	535.3M	562.1M
Net Tangible Assets	128.7M	258.7M	169.1M	326.6M	375.5M	394.3M
Net Debt	(136.4M)	(185.4M)	(149.0M)	(238.8M)	(208.2M)	(218.6M)
Retained Earnings	(130.3M)	(209.5M)	(310.3M)	(422.3M)	(574.1M)	(545.4M)
Accounts Payable	947K	3.4M	6.7M	8.0M	7.0M	4.3M
Cash	136.4M	187.2M	150.5M	249.8M	234.2M	162.6M
Non Current Assets Total	69K	2.0M	2.0M	1.4M	20.3M	21.3M
Non Currrent Assets Other	29K	161K	417K	108K	(1.0)	(0.95)
Other Assets	69K	201K	417K	108K	1.0	0.95
Cash And Short Term Investments	136.4M	268.4M	188.3M	351.4M	550.0M	577.5M
Common Stock Shares Outstanding	15.1M	31.5M	34.8M	39.0M	52.6M	34.6M
Short Term Investments	71.6M	81.1M	37.8M	101.7M	315.8M	331.6M
Liabilities And Stockholders Equity	138.1M	273.3M	195.5M	356.6M	580.3M	609.3M
Non Current Liabilities Total	23K	1.5M	1.3M	10.9M	25.8M	19.4M
Other Current Assets	1.6M	3.0M	5.3M	3.7M	10.0M	10.4M
Other Stockholder Equity	120.9M	468.2M	479.4M	748.9M	1.1B	1.2B
Total Liab	9.4M	14.6M	26.4M	30.0M	45.0M	29.5M
Net Invested Capital	128.7M	258.7M	169.1M	336.1M	560.3M	588.3M
Total Current Assets	138.0M	271.3M	193.6M	355.2M	560.0M	588.0M
Accumulated Other Comprehensive Income	(6K)	(3K)	(27K)	37K	270K	283.5K
Net Working Capital	128.7M	258.2M	168.5M	336.1M	540.8M	567.9M
Capital Surpluse	259.0M	468.2M	479.4M	748.9M	861.2M	438.3M

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.

Try AI Portfolio Architect

When determining whether Akero Therapeutics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Akero Therapeutics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Akero Therapeutics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Akero Therapeutics Stock:

How To Invest In Akero

Details

Is Akero Stock a good investment?

Details

What is Akero Therapeutics' Net Worth?

Details

Largest Biotechnology Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Akero Therapeutics. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in metropolitan statistical area.

To learn how to invest in Akero Stock, please use our How to Invest in Akero Therapeutics guide.

You can also try the Equity Analysis module to research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities.

Complementary Tools for Akero Stock analysis

When running Akero Therapeutics' price analysis, check to measure Akero Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Akero Therapeutics is operating at the current time. Most of Akero Therapeutics' value examination focuses on studying past and present price action to predict the probability of Akero Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Akero Therapeutics' price. Additionally, you may evaluate how the addition of Akero Therapeutics to your portfolios can decrease your overall portfolio volatility.

	Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios
	Portfolio Comparator Compare the composition, asset allocations and performance of any two portfolios in your account
	FinTech Suite Use AI to screen and filter profitable investment opportunities
	Share Portfolio Track or share privately all of your investments from the convenience of any device
	Sync Your Broker Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors.
	Insider Screener Find insiders across different sectors to evaluate their impact on performance
	My Watchlist Analysis Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like
	Money Flow Index Determine momentum by analyzing Money Flow Index and other technical indicators

Is Akero Therapeutics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Akero Therapeutics. If investors know Akero will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Akero Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Earnings Share

(3.24)

Return On Assets

(0.20)

Return On Equity

(0.31)

The market value of Akero Therapeutics is measured differently than its book value, which is the value of Akero that is recorded on the company's balance sheet. Investors also form their own opinion of Akero Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Akero Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Akero Therapeutics' market value can be influenced by many factors that don't directly affect Akero Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Akero Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Akero Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Akero Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Akero Capital Surpluse vs Net Invested Capital Analysis

Capital Surpluse vs Net Invested Capital

Capital Surpluse vs Net Invested Capital Correlation Analysis

Correlation Coefficient

Capital Surpluse

Net Invested Capital

Akero Therapeutics fundamental ratios Correlations

Akero Therapeutics Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Akero Therapeutics fundamental ratios Accounts

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

Complementary Tools for Akero Stock analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Cash And Short Term Investments	+ 1.0	Total Assets
Total Current Assets	+ 1.0	Total Assets
Net Working Capital	+ 1.0	Total Assets
Net Invested Capital	+ 1.0	Total Stockholder Equity
Total Current Assets	+ 1.0	Cash And Short Term Investments
Net Working Capital	+ 1.0	Cash And Short Term Investments

Net Working Capital	- 0.98	Retained Earnings
Total Current Assets	- 0.98	Retained Earnings
Cash And Short Term Investments	- 0.98	Retained Earnings
Cash	- 0.98	Net Debt
Retained Earnings	- 0.98	Total Assets
Net Invested Capital	- 0.97	Retained Earnings